Minovia Therapeutics

Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trial for Pearson Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical...

Biotechnology,cell therapy,rare diseases,mitochondria,mitochondrial diseases,mitochondrial augmentation,and mitochondrial dysfunction

Minovia therapeutics operates in the Biotechnology research industry.

Minovia therapeutics's revenue is 11m - 100m

Minovia therapeutics has 11 - 50 employees.